Intensity (INTS) Q2 Net Loss Drops 50%
Intensity Therapeutics (NASDAQ:INTS), a clinical-stage biotechnology company focused on direct tumor-targeted treatments, released its second quarter 2025 earnings on August 7, 2025. The quarter’s headline news is a significant reduction in operating expenses, achieved while maintaining advances in clinical research for its lead drug candidate, INT230-6. As reported, earnings per share came in at $(0.13), improving markedly from the $(0.36) net loss per share in the prior year. No revenue was reported or expected, as is standard for a pre-commercial biotech. Overall, the period was defined by prudent financial management, with substantial cost-cutting, decisive capital raising, and progress in key clinical programs despite funding pressures.
Source: Analyst estimates for the quarter provided by FactSet.
Intensity Therapeutics is developing anti-cancer therapies using its proprietary DfuseRx drug delivery platform. The platform allows better dispersion of drugs directly within tumors, aiming to maximize cancer cell destruction while minimizing side effects common to systemic therapies.
Source Fool.com
